Raising AMD awareness

Article

Novartis Pharmaceuticals UK Ltd, supported by the Royal National Institute of Blind People (RNIB), has launched "Be AMD Aware", a campaign to raise awareness of the risk factors for and symptoms of age-related macular generation (AMD) among those aged 55 and over in the UK.

Novartis Pharmaceuticals UK Ltd, supported by the Royal National Institute of Blind People (RNIB), has launched "Be AMD Aware", a campaign to raise awareness of the risk factors for and symptoms of age-related macular generation (AMD) among those aged 55 and over in the UK.

The awareness campaign was prompted by survey results that showed that 44% of respondents were completely unaware of the condition. The telephone survey - of 519 UK adults (aged ≥50 years), which was conducted by Harris Interactive between November and December 2008 - also showed that 90% of respondents were unable to identify the symptoms of AMD and 70% were unaware that smoking constituted a significant risk for AMD development.

The "Be AMD Aware" campaign aims to encourage over-55s in the UK to undergo regular eye examinations and to become more aware of AMD symptoms to enable early detection. Information for the general public is available at www.beAMDaware.co.uk.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.